Astellas Pharma EBIT

Astellas Pharma posts a EBIT of $420B as of June 2026. That compares with $270B in the prior-year period — up 55.4% year over year. That is above the Healthcare sector average of $110B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Astellas Pharma's EBIT was $270B. The latest reading is $420B — a 55.4% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a EBIT near $110B is typical. Astellas Pharma's $420B is higher that level. That is roughly 292.0% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Astellas Pharma's financial statement story. At $420B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 4503.T's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $110B), and (3) consistency with growth and profitability. This page covers the first two; Astellas Pharma's other metric pages and overview cover the third.